🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Just published in Journal of Clinical Oncology the updated ASCO guidelines on fertility preservation in people with #cancer: a must read for all colleagues involved in cancer care to increase awareness on #oncofertility issues OncoAlert Ann Partridge MD, MPH Oncofertility Link: ascopubs.org/doi/10.1200/JC…

"In labs around the world, scientists are using A.I. to search among existing medicines for treatments that work for rare diseases." And saving some lives. David Fajgenbaum, MD nytimes.com/2025/03/20/wel…

I'm excited to be a keynote speaker for this year's Dawn S graduates!

A BIG STUDY in Nature Medicine: Which food makes you age faster? Scientists looked at 105,000 people in 30 years. The statistics is impressive. The study is open-access, so everyone can read it. 📍 Findings: The diet that ROCKS: fruits, vegetables, whole grains, unsaturated

As a med student with 2 weeks to live, David Fajgenbaum, MD did something unexpected: Found a cure using a repurposed drug on himself. In this ReThinking, he talks with Adam Grant about how this approach to medicine could save others, too. Listen now: t.ted.com/WkR1XfV

Love to see this!

Running out of known treatments for a disease doesn’t mean there are no treatments. Medicines can be effective for more diseases than they’re approved for. Companies develop drugs for specific diseases & other possibilities are often never explored. Every Cure is changing that!

2. GLP1s might protect against dementia in people with type 2 diabetes This is a meta-analysis of randomised trials, looking at GLP1 receptor agonists (or other diabetes medications) vs. usual care in people with type 2 diabetes GLP1s (but not other diabetes medications)

4. A new approach for myasthenia gravis Myasthenia gravis causes muscle weakness that gets worse with exertion It's an autoimmune condition, so it's driven by B cells, but B cell-depleting antibodies that target CD20 have had inconsistent results CD19 is expressed more broadly

"Approximately 5%of annual cancer diagnoses or 100,000 cancers were projected to result from [U.S.] CT utilization in 2023. "jamanetwork.com/journals/jamai…

Love seeing this progress by Eric Vallabh Minikel and his wife Sonia who are chasing her cure for fatal familial insomnia. news.harvard.edu/gazette/story/…

For the first time in 45 years, a new subtype of Castleman disease was discovered by David Fajgenbaum, MD and colleagues, allowing patients who have been caught between existing classification systems to receive the right treatment for their condition. spr.ly/60182nxog

The inspiring life journey of David Fajgenbaum, MD is set to become a feature film. The movie aims to capture his determination and crowdsourced research that led to finding his own cure for Castleman Disease using an already FDA-approved drug. spr.ly/60102o5Du

What an inspiring keynote by David Fajgenbaum, MD Every Cure . A story of hope, perseverance and success. Looking forward to the movie! #coa2025 Community Oncology

Spectacular keynote by David Fajgenbaum, MD of U Penn - he is the author of “@chasingmycure” and is working in the space of repurposing the existing drugs for challenging disease scenarios. Community Oncology #COA2025 Dr. Patt Hem-Onc Fellows Network Hematology & Oncology Women Physicians Group—HOWPG IMG Oncologists

Congrats David Fajgenbaum, MD on making the 2025 TIME 100 Health list! Fajgenbaum survived rare Castleman disease by discovering an existing drug could save his life. Now, he's using AI to repurpose FDA-approved drugs, saving lives with existing solutions. spr.ly/6010NyVKq

“During difficult times, we’re often told to look for silver linings. But my mom taught me that we should look to create them. What is a problem that you’re obsessed with solving or that you’re hoping someone will change? Chase after that.” David Fajgenbaum, MD (M’13, WG’15)

Today, we’re announcing the first major discovery made by our AI Scientist with the lab in the loop: a promising new treatment for dry AMD, a major cause of blindness. Our agents generated the hypotheses, designed the experiments, analyzed the data, iterated, even made figures

In this conversation, David Fajgenbaum, MD discusses his personal diagnostic journey and the errors and delays he encountered along the way. We also explore why academic medicine needs to go beyond generating disparate pieces of scientific knowledge. ow.ly/re6150VWHn0

“You need to have a vision for what you’re fighting for.” During his keynote speech to our Executive MBA Class of 2025, David Fajgenbaum, MD (M’13, WG’15) of Penn Medicine and Every Cure shared what his health journey taught him about overcoming life’s greatest challenges.